Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions

International Journal of Pharmaceutics

Volumn 392, Issue 1-2, 2010, Pages 64-71

  Zhao, Yong Xing ^a   Hua, Hai Ying ^a   Chang, Min ^a   Liu, Wei Jing ^a   Zhao, Yang ^a   Liu, Hong Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cytotoxicity; High pressure homogenization; Hydroxycamptothecin; Nanosuspensions; Precipitation

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYCAMPTOTHECIN; MANNITOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CRYSTAL; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRY POWDER; FREEZE DRYING; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NANOPHARMACEUTICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; SUSPENSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALORIMETRY, DIFFERENTIAL SCANNING; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; INHIBITORY CONCENTRATION 50; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 77952741121     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.027     Document Type: Article

References (37)

1. Burke T.G., Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem. 1993, 212:285-287.
2. Constantinides P.P., Chaubal M.V., Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 2008, 60:757-767.
3. Croce A.C., Bottiroli G., Supino R., Favini E., Zuco V., Zunino F. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem. Pharmacol. 2004, 67:1035-1045.
4. Han J.Y., Lee D.H., Lee S.Y., Park C.G., Kim H.Y., Lee H.G., Lee G.G., Kim H.T., Lee J.S. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer 2005, 104:2759-2765.
5. Hertzberg R.P., Caranfa M.J., Holden K.G., Jakas D.R., Gallagher G., Mattern M.R., Mong S.M., Bartus J.O., Johnson R.K., Kingsbury W.D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32:715-720.
6. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260:14873-14878.
7. Hwang K.J., Liu H.C. Cross-flow microfiltration of aggregated submicron particles. J. Membr. Sci. 2002, 201:137-148.
8. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
9. Kipp, J.E., Wong, J.C.T., Doty, M.J., Rebbeck, C.L., 2003. Microprecipitation Method For Preparing Submicron Suspensions. United States Patent 6,607,784, Baxter International Inc. (Deerfield, IL), USA, 2003.
10. Kocbek P., Baumgartner S., Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 2006, 312:179-186.
11. Müller R.H. Zetapotential und Partikelladung-Kurze Theorie, praktische Messdurchfuhrung, Dateninterpretation 1996, Wissenschaftliche, Stuttgart.
12. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47:3-19.
13. Müller R.H., Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 2004, 113:151-170.
14. Mallery S.R., Shenderova A., Pei P., Begum S., Ciminieri J.R., Wilson R.F. Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. Anticancer Res. 2001, 21:1713-1722.
15. Markman M. Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. Oncologist 2005, 10:695-697.
16. Minko T., Paranjpe P.V., Qiu B., Lalloo A., Won R., Stein S., Sinko P.J. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 2002, 50:143-150.
17. Moschwitzer J., Achleitner G., Pomper H., Muller R.H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 2004, 58:615-619.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
19. Paranjpe P.V., Stein S., Sinko P.J. Tumor-targeted and activated bioconjugates for improved camptothecin delivery. Anticancer Drugs 2005, 16:763-775.
20. Peters K., Leitzke S., Diederichs J.E., Borner K., Hahn H., Müller R.H., Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 2000, 45:77-83.
21. Pu X., Sun J., Wang Y., Liu X., Zhang P., Tang X., Pan W., Han J., He Z. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int. J. Pharm. 2009, 379:167-173.
22. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
23. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 1997, 8:837-855.
24. Sadzuka Y., Takabe H., Sonobe T. Liposomalization of SN-38 as active metabolite of CPT-11. J. Control. Release 2005, 108:453-459.
25. Saetern A.M., Brandl M., Bakkelund W.H., Sveinbjornsson B. Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anticancer Drugs 2004, 15:899-906.
26. Teeranachaideekul V., Junyaprasert V.B., Souto E.B., Müller R.H. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm. 2008, 354:227-234.
27. Van Eerdenbrugh B., Froyen L., Van Humbeeck J., Martens J.A., Augustijns P., Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur. J. Pharm. Sci. 2008, 35:127-135.
28. Wang B.H., Zhang W.B., Zhang W., Mujumdar A.S., Huang L.X. Progress in drying technology for nanomaterials. Dry. Technol. 2005, 23:7-32.
29. Wani M.C., Ronman P.E., Lindley J.T., Wall M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem. 1980, 23:554-560.
30. Williams J., Lansdown R., Sweitzer R., Romanowski M., LaBell R., Ramaswami R. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J. Control. Release 2003, 91:167-172.
31. Yang L., Cui F., Cun D.M., Tao A., Shi K., Lin W.H. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int. J. Pharm. 2007, 340:163-172.
32. Yonemori K., Katsumata N., Yamamoto N., Kasamatsu T., Yamada T., Tsunematsu R., Fujiwara Y. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer 2005, 104:1204-1212.
33. Zhang L., Li S., Liao H., Jiang W.Q., Guan Z.Z. Phase I trial of pharmacokinetics and human tolerability to 10-hydroxycamptothecin in patients with advanced malignancy. Ai Zheng 2001, 20:1391-1395.
34. Zhang L.Y., Yang M., Wang Q., Li Y., Guo R., Jiang X.Q., Yang C.Z., Liu B.R. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Control. Release 2007, 119:153-162.
35. Zhang Y., Yang M., Portney N.G., Cui D., Budak G., Ozbay E., Ozkan M., Ozkan C.S. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed. Microdevices 2008, 10:321-328.
36. Zhao Y., Gao J., Sun X., Chen H., Wu L., Liang W. Enhanced nuclear delivery and cytotoxic activity of hydroxycamptothecin using o/w emulsions. J. Pharm. Pharm. Sci. 2007, 10:61-70.
37. Zhao Y.X., Gao J.Q., Qiao H.L., Chen H.L., Liang W.Q. Development and validation of a sensitive reversed-phase HPLC method to determine intracellular accumulation of hydroxycamptothecin. J. Pharm. Biomed. Anal. 2006, 41:1007-1010.